草酸铂介入联合羟基喜树碱腹腔灌注治疗直肠癌术后复发

Oxaliplatin Intra-Arterial Infusion Combined with Hydroxycamptothecin Peritoneal Infusion for Treatment of Relapse Rectal Cancer

目的研究草酸铂动脉介入联合羟基喜树碱(拓喜)腹腔灌注治疗直肠癌术后复发的近期疗效和毒副反应。方法40例直肠癌术后复发病例,草酸铂150mg/m2动脉介入d1和羟基喜树碱10mgd1～5腹腔灌注,28d一周期。治疗2周期评价疗效和毒副反应。结果完全缓解(CR)6例,部分缓解(PR)20例,总有效率65%,1年生存率59.4%;Ⅲ～Ⅳ度粒细胞减少2.5%,Ⅲ度腹泻5%。结论草酸铂动脉介入联合羟基喜树碱腹腔灌注治疗直肠癌术后复发疗效明确,毒副作用小,可明显改善患者症状提高生存质量。

Objective： To investigate the efficacy and safety of Oxaliplatin intra-arterial infusion combined with Hydroxycampyotbecin peritoneal infusion for treatment of relapse rectal cancer. Methods： Forty cases of relapse rectal cancer were treated by intra-Arterial infusion oxaliplatin at 150 mg/m^2 d1 combined with peritoneal infusion Hhdroxycamplathecin at 10 mg d1 ～5,every four weeks. Then after 2 cycles of treatment ,the efficacy and clinical symptoms were evaluate. Resuhs：There were 6/40 achieved CR.20/40 ：achieved PR,the response rate was 65%,and the 1 year survival was 59.4%.Hematologic toxicities,which were mild ,included grade Ⅲ - Ⅳ neutropenia in 2.5%. The common nonhematologic toxicities included grade Ⅲ nausea and vomitin 2.5%, Ⅲ diarrhea 5%. Conclusion： Oxaliplalin intra-aryerial infusion combined Hydroxycamplothecin peritoneal infusion for treatment of relapse rectal cancer is safe and effective. This treatment can improve the symptoms and life quality of patients.